RxDoctor Payments Data

Helda Bacall

Family · Detroit, MINPI 1134731466

Payments from drug & device makers

$9,043in general payments, 2019–2025

Across 63 payments — averaging $143.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Janssen Scientific Affairs, LLC$579
  • Astellas Pharma US Inc$375
  • AstraZeneca$341
  • Seagen Inc.$308
  • Exelixis Inc.$290
  • plus $969 from 11 others

What the payments were for

  • Consulting fees$5636%
  • Speaking & faculty fees$4,85054%
  • Travel & lodging$6227%
  • Food & beverage$2,20124%
  • Education$8089%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,043 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$3,036
Medicare patients
31
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide144$1,199,628
CabometyxCabozantinib S-Malate43$1,046,807
OrgovyxRelugolix164$418,578
NubeqaDarolutamide28$251,172
Pazopanib Hcl26$173,266
Abiraterone Acetate114$62,656
Prednisone126$558
Venlafaxine Hcl ErVenlafaxine Hcl33$260
Megestrol Acetate13$172
Ondansetron Hcl16$160
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$155
Tamsulosin Hcl13$52
Famotidine17$47
Amlodipine Besylate15$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$375$1,199,628144 claims
Exelixis Inc.Cabometyx$290$1,046,80743 claims
Sumitomo Pharma America, Inc.Orgovyx$73$418,578164 claims
BayerNubeqa$152$251,17228 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$579$62,656114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →